Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAlphamab-B
Stock Code09966
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中國領先的臨床階段生物製藥公司,在雙特異性及蛋白質工程方面擁有全面整合的專有生物製劑平台,開發腫瘤候選藥物。
Listing Date2019-12-12
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)江蘇省蘇州市蘇州工業園區星湖街218號C23樓401和501室
Business Address (Hong Kong)銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitealphamabonc.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 10.20 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-12-02 to 2019-12-05
Global Offering Shares179,403,000 shares
HK Public Offer Shares (Initial)17,942,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)161,461,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO897,011,575 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,829,910,600

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 10,200
2 lots 2,000 HK$ 20,400
3 lots 3,000 HK$ 30,600
4 lots 4,000 HK$ 40,800
5 lots 5,000 HK$ 51,000
6 lots 6,000 HK$ 61,200
7 lots 7,000 HK$ 71,400
8 lots 8,000 HK$ 81,600
9 lots 9,000 HK$ 91,800
10 lots 10,000 HK$ 102,000
15 lots 15,000 HK$ 153,000
20 lots 20,000 HK$ 204,000
25 lots 25,000 HK$ 255,000
30 lots 30,000 HK$ 306,000
35 lots 35,000 HK$ 357,000
40 lots 40,000 HK$ 408,000
45 lots 45,000 HK$ 459,000
50 lots 50,000 HK$ 510,000
60 lots 60,000 HK$ 612,000
70 lots 70,000 HK$ 714,000
80 lots 80,000 HK$ 816,000
90 lots 90,000 HK$ 918,000
100 lots 100,000 HK$ 1,020,000
200 lots 200,000 HK$ 2,040,000
300 lots 300,000 HK$ 3,060,000
400 lots 400,000 HK$ 4,080,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
500 lots 500,000 HK$ 5,100,000
600 lots 600,000 HK$ 6,120,000
700 lots 700,000 HK$ 7,140,000
800 lots 800,000 HK$ 8,160,000
900 lots 900,000 HK$ 9,180,000
1,000 lots 1,000,000 HK$ 10,200,000
2,000 lots 2,000,000 HK$ 20,400,000
3,000 lots 3,000,000 HK$ 30,600,000
4,000 lots 4,000,000 HK$ 40,800,000
5,000 lots 5,000,000 HK$ 51,000,000
6,000 lots 6,000,000 HK$ 61,200,000
7,000 lots 7,000,000 HK$ 71,400,000
8,000 lots 8,000,000 HK$ 81,600,000
8,971 lots 8,971,000 HK$ 91,504,200

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 7.73B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +21%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status亏损人民币202.6百万元
Period-End Cash Balance人民币633.7百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20172018
Other income and gains, net 1,428-9,050
Administrative expenses -13,025-25,857
Operating profit -64,818-201,126
Net finance costs -8-1,507
Profit before tax -64,826-202,633
Income tax expense 00
Profit for the year -64,826-202,633
Profit attributable to owners -33,061-149,843
Balance Sheet
Item 201720182019-06
Cash and cash equivalents 57633,712
Inventories 3,4867,068
Total current assets 11,215656,103
Total assets 46,577826,893
Total current liabilities 10,26682,800
Total liabilities 20,2661,093,921
Total equity 26,311-267,028
Equity attributable to owners 13,419-267,028
Interest-bearing borrowings 0100,000150,000
Cash Flow Statement
Item 201720182019-06
Net cash from operating activities -65,161-93,874
Net cash from investing activities 2,305-72,110
Net cash from financing activities 2,000798,800
Net increase in cash 12642,353
Depreciation of PP&E 101266344
Depreciation of right-of-use assets 4136,2964,685
Purchase of PP&E -34,000-48,900-1,680
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 13.5
First Day OpenHK$ 13.0
First Day Change32.35%
First Day Volume115582000.0
First Day Turnover1499270000.0
Use of Proceeds
1、約50%(或854.6百萬港元)將用于我們的核心產品KN046的研發及商業化; 2、約20%(或341.8百萬港元)將用于KN026的研發及商業化; 3、約5%(或85.5百萬港元)將用于KN019的研發; 4、約15%(或256.4百萬港元)將用于我們于蘇州的新制造及研發設施的建設; 5、約10%(或170.9百萬港元)將用于我們的早期管線及作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 中信证券(香港)有限公司 CE AAK249 Jefferies Hong Kong Limited CE ATS546
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 中信里昂证券有限公司 CE AAB893 Jefferies Hong Kong Limited CE ATS546
Joint Bookrunners (7)
Morgan Stanley Asia Limited CE AAD291 中信里昂证券有限公司 CE AAB893 Jefferies Hong Kong Limited CE ATS546 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 中银国际亚洲有限公司 CE AET863
Joint Lead Managers (7)
Morgan Stanley Asia Limited CE AAD291 中信里昂证券有限公司 CE AAB893 Jefferies Hong Kong Limited CE ATS546 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 中银国际亚洲有限公司 CE AET863

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Lake Bleu Prime Healthcare Master Fund Limited 103,193,400 HKD — 5.60% — 6 months 2020-06-12
2 Matthews Asia Funds 192,616,800 HKD — 10.50% — 6 months 2020-06-12
3 OrbiMed Funds 137,608,200 HKD — 7.50% — 6 months 2020-06-12
4 景林资产管理有限公司 137,577,600 HKD — 7.50% — 6 months 2020-06-12
5 绿叶制药集团有限公司 34,394,400 HKD — 1.90% — 6 months 2020-06-12
6 摩根士丹利亚洲有限公司 103,183,200 HKD — 5.60% — 6 months 2020-06-12
7 泰康人寿保险有限责任公司 206,376,600 HKD — 11.30% — 6 months 2020-06-12

Directors & Management

PositionChinese nameEnglish Name
Chairman徐霆—
Company Secretary帥琪、黃綺汶—
No director data available.

Major Shareholders

Major Shareholders & Holdings徐博士(透過Rubymab)緊隨全球發售完成後持股約36.62%,為控股股東;張喜田先生(透過Sky Diamond)9.56%;薛傳校先生(透過Pearlmed)9.56%;PAG Growth 5.54%;Advantech II 5.51%。
About this page

This page shows Alphamab-B (09966) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect